VivoSim Labs (NASDAQ:VIVS) Announces Quarterly Earnings Results

VivoSim Labs (NASDAQ:VIVS) issued its earnings results on Thursday. The company reported ($0.98) EPS for the quarter, FiscalAI reports. The firm had revenue of $0.03 million during the quarter. VivoSim Labs had a negative return on equity of 32.95% and a negative net margin of 1,396.48%.

VivoSim Labs Stock Performance

Shares of VivoSim Labs stock traded down $0.01 during midday trading on Friday, hitting $2.18. 46,286 shares of the company were exchanged, compared to its average volume of 490,741. The firm has a 50 day simple moving average of $2.96. The company has a market capitalization of $5.69 million, a price-to-earnings ratio of -0.43 and a beta of 1.18. VivoSim Labs has a 52 week low of $1.41 and a 52 week high of $21.96.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of VivoSim Labs in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

VivoSim Labs Company Profile

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.